BioSpace News Archive

With ZEISS Visioner 1, ZEISS is launching an innovative digital microscope that for the first time enables all-in-one focus in real time thanks to its Micro-mirror Array Lens System (MALS™).

Nikon Instruments Inc., innovator of advanced microscope systems, today announced the release of the ECLIPSE Si biological microscope , with intelligent time-saving features, an automatic shut-off mode, and an ergonomic design to reduce physical strain that can occur with prolonged microscope use.

AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, today announced a new collaboration with AstraZeneca

Exasol, the high-performance analytics database, announced that Pharmascience Inc., a leading Canadian manufacturer of prescription, over-the-counter, and behind-the-counter generic pharmaceuticals, has selected Exasol to give end-users faster, more efficient access to data.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, a critical step in the company’s ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.

Scientific Bioprocessing, Inc., a subsidiary of publicly-owned Scientific Industries, Inc., announced the launch of its Intelligent, Dynamic Fiber Optic Kit.

SquareWorks Consulting, a leading provider of NetSuite Consulting Services and NetSuite Solutions, is announcing the launch of Biotech-focused NetSuite implementation services.

Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced that the Company will present at The Microcap Rodeo Winter Wonderland Conference on February 17, 2021 at 2:30pm EST.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company’s proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice.

The CDC communicated that approximately 25.5 million doses of the Moderna COVID-19 Vaccine have been administered in the U.S.